KenH
Well-Known Member
"Merck submitted molnupiravir to the FDA to consider for emergency authorization on October 11, 2021—71 days ago. Randomized controlled trials show the drug prevents 30 percent of symptomatic cases from progressing to severe disease. No patient receiving molnupiravir died of COVID-19. The U.K. Medicine and Healthcare Products Regulatory Agency approved its use in Britain on November 4. On November 30 an FDA advisory committee recommended its approval but the FDA has yet to act on the recommendation.
Pfizer submitted its antiviral drug Paxlovid to the FDA for emergency use authorization on November 16 after controlled trials found it to be 89 percent effective in preventing hospitalization. There were no deaths reported in any patient receiving Paxlovid.
Both drugs were so effective that trials were interrupted because it was unethical to deny the drug to the trials’ placebo arms."
American Patients Held Hostage Day 71 | Cato at Liberty Blog
Pfizer submitted its antiviral drug Paxlovid to the FDA for emergency use authorization on November 16 after controlled trials found it to be 89 percent effective in preventing hospitalization. There were no deaths reported in any patient receiving Paxlovid.
Both drugs were so effective that trials were interrupted because it was unethical to deny the drug to the trials’ placebo arms."
American Patients Held Hostage Day 71 | Cato at Liberty Blog